News Releases

April 4, 2022
- Novel approach to CD28 to enhance activation of T cells and anti-tumor activity - - Crystallography demonstrates critical interaction between davoceticept’s CD80 domain and PD-L1 - - Data further encourage ongoing davoceticept development, including NEON-1 monotherapy and NEON-2 pembrolizumab
Displaying 21 - 30 of 32